SRE
40
3
K
48
3
CLX
62
-3
KR
46
-4
PFG
30
3
JNJ
35
5
BBY
46
-2
EQT
50
3
AA
31
4
BLK
50
3
WBA
38
-3
HAL
30
-10
LLY
45
8
PBI
32
2
DAL
61
3
RL
75
2
TRIP
64
4
CINF
35
11
MCHP
36
3
NUE
39
2
SRE
40
3
K
48
3
CLX
62
-3
KR
46
-4
PFG
30
3
JNJ
35
5
BBY
46
-2
EQT
50
3
AA
31
4
BLK
50
3
WBA
38
-3
HAL
30
-10
LLY
45
8
PBI
32
2
DAL
61
3
RL
75
2
TRIP
64
4
CINF
35
11
MCHP
36
3
NUE
39
2
Financhill
Back

Ligand Pharmaceuticals 10K Form

Sell
48

LGND
Ligand Pharmaceuticals

Last Price:
$113.45
Seasonality Move:
9.17%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-08 10Q LGND/Ligand Pharmaceuticals Quarterly
2023-11-09 10Q LGND/Ligand Pharmaceuticals Quarterly
2023-08-09 10Q LGND/Ligand Pharmaceuticals Quarterly
2023-05-08 10Q LGND/Ligand Pharmaceuticals Quarterly
2022-11-08 10Q LGND/Ligand Pharmaceuticals Quarterly
2022-08-09 10Q LGND/Ligand Pharmaceuticals Quarterly

Receive LGND News And Ratings

See the #1 stock for the next 7 days that we like better than LGND

LGND Financial Statistics

Sales & Book Value

Annual Sales: $131.3M
Cash Flow: $22.3M
Price / Cash Flow: 294.97
Annual Sales: $44.84
Price / Book: 2.56

Profitability

EPS (TTM): 2.51000
Net Income (TTM): $45.2M
Gross Margin: $120.8M
Return on Equity: 5.97%
Return on Assets: 5.27%

Ligand Pharmaceuticals Earnings Forecast

Key Ligand Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 30 years for LGND is 91.99%.
  • The Selling, General & Administrative Expenses for LGND have been equal to 40.20% of Gross Profit Margin.
  • The Research & Development expenses have been 18.69% of Revenue.
  • The Interest Expense is 1.26% of Operating Income.
  • The Net Earning history of LGND is 39.72% of Total Revenues.
  • Per Share Earnings over the last 30 years have been positive in 19 years.

Ligand Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: LGND
CUSIP: 53220K
Website: ligand.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 12.49
Quick Ratio: 10.57

Price-to-Earnings

Trailing P/E Ratio: 38.71
Forward P/E Ratio: 18.54

LGND Technical Analysis vs Fundamental Analysis

Sell
48
Ligand Pharmaceuticals (LGND) is a Sell

Is Ligand Pharmaceuticals a Buy or a Sell?